Mechanisms of resistance to androgen deprivation therapy in prostate cancer.

Authors

Imane Bensalim, Lahcen Belyamani, Saber Boutayeb, Ilhame Bourais

Published in

Molecular aspects of medicine. Volume 110. Pages 101488. Jun 18, 2026. Epub Jun 18, 2026.

Abstract

Prostate cancer is among the top causes of cancer-related mortality in men, according to the latest data from GLOBOCAN, driven primarily by androgen receptor signaling and initially treated with androgen deprivation therapy. However, most patients progress to a resistant state characterized by mechanisms such as receptor amplification, mutations, splice variants, and activation of alternative pathways. This review summarizes the key molecular drivers of resistance and evaluates emerging invasive biomarkers with potential clinical utility, though most remain insufficiently validated. It also outlines current and emerging therapeutic strategies to overcome resistance, highlighting ongoing challenges in clinical implementation.

PMID:
42314224
Bibliographic data and abstract were imported from PubMed on 19 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.